Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial

被引：0

作者：

Gabe S. Sonke

Lowell L. Hart

Mario Campone

Frans Erdkamp

Wolfgang Janni

Sunil Verma

Cristian Villanueva

Erik Jakobsen

Emilio Alba

Erik Wist

Anne M. Favret

Thomas Bachelot

Roberto Hegg

Paul Wheatley-Price

Farida Souami

Santosh Sutradhar

Michelle Miller

Caroline Germa

Howard A. Burris

机构：

[1] Netherlands Cancer Institute/BOOG Study Center,Department of Medical Oncology

[2] Florida Cancer Specialists,Zuyderland Medical Center

[3] Sarah Cannon Research Institute,University Hospital of Besançon

[4] Institut de Cancérologie de l’Ouest – René Gauducheau Centre de Recherche en Cancérologie,Virginia Cancer Specialists PC

[5] Sittard-Geleen/Heerlen,Ottawa Hospital Research Institute

[6] Universitätsklinikum Ulm,undefined

[7] Tom Baker Cancer Centre,undefined

[8] Hospital Jean-Minjoz,undefined

[9] Lillebælt Hospital,undefined

[10] Hospital Universitario Virgen de la Victoria,undefined

[11] IBIMA,undefined

[12] Oslo University Hospital,undefined

[13] US Oncology,undefined

[14] Centre Léon Bérard,undefined

[15] Hospital Pérola Byington Centro de Referência da Saúde da Mulher,undefined

[16] University of Ottawa,undefined

[17] Novartis Pharma AG,undefined

[18] Novartis Pharmaceuticals Corporation,undefined

来源：

Breast Cancer Research and Treatment | 2018年 / 167卷

关键词：

Breast cancer; CDK inhibitor; Ribociclib; Endocrine therapy; Elderly; Hormone receptor-positive;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：659 / 669

页数：10

共 50 条

[11] First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results.
Janni, Wolfgang
Burris, Howard A.
Blackwell, Kimberly L.
Hart, Lowell L.
Chan, Arlene
Nusch, Arnd
Burdaeva, Olga Nikolaevna
Alba, Emilio
Yardley, Denise A.
Bachelot, Thomas Denis
Gil, Miguel J. Gil
Richards, Donald A.
Sparano, Joseph A.
Kattan, Joseph Gergi
Bourgeois, Hugues Pierre
El Karak, Fadi Rafic
Ramaswamy, Bhuvaneswari
Sutradhar, Santosh C.
Miller, Michelle Kristine
Conte, Pier Franco
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[12] Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib 1 letrozole in hormone receptor-positive (HR1), HER2-negative (HER2-) advanced breast cancer (ABC)
Spazzapan, S.
Conte, P.
Simoncini, E.
Campone, M.
Miller, M.
Sonke, G.
ANNALS OF ONCOLOGY, 2017, 28
[13] Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (vol 29, pg 1541, 2018)
Hortobagyi, G. N.
Stemmer, S. M.
Burris, H. A.
Yap, Y. S.
Sonke, G. S.
Paluch-Shimon, S.
Campone, M.
Petrakova, K.
Blackwell, K. L.
Winer, E. P.
Janni, W.
Verma, S.
Conte, P.
Arteaga, C. L.
Cameron, D. A.
Mondal, S.
Su, F.
Miller, M.
Elmeliegy, M.
Germa, C.
O'Shaughnessy, J.
ANNALS OF ONCOLOGY, 2019, 30 (11) : 1842 - 1842
[14] Ribociclib plus letrozole vs placebo plus letrozole in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) and a high disease burden
Verma, S.
Gil-Gil, M.
Hegg, R.
Wheatley-Price, P.
Kattan, J.
Bourgeois, H.
Sutradhar, S.
Miller, M.
Campone, M.
ANNALS OF ONCOLOGY, 2017, 28
[15] Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
Lopez-Tarruella, Sara
Jerez, Yolanda
Marquez-Rodas, Ivan
Echavarria, Isabel
Martin, Miguel
FUTURE ONCOLOGY, 2017, 13 (24) : 2137 - 2149
[16] The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer
Fjermeros, Kamilla
Ghannoum, Salim
Geisler, Stephanie B.
Bhargava, Sameer
Tahiri, Andliena
Klajic, Jovana
Luders, Torben
Fongard, Marie
Nawaz, Meh Sameen
Bosnjak-Olsen, Tatjana
Buvarp, Unn-Cathrin Edvardsen
Johanna Rosenskiold, Aino Katri
Nguyen, Nam Thi
Sletbak, Tone Tysko
Seyedzadeh, Manouchehr
Selsas, Knut
Porojnicu, Alina Carmen
Skjerven, Helle Kristine
Hovda, Tone
Sahlberg, Kristine Kleivi
Torland, Lilly Anne
Lyngra, Marianne
Hammarstrom, Clara Louise
Honigsperger, Elma Bahonjic
Noone, John Christopher
Mathiassen, Silje
Hurtado, Antoni
Goel, Shom
Koff, Andrew
Tekpli, Xavier
Kristensen, Vessela N.
Geisler, Juergen
FUTURE ONCOLOGY, 2024, 20 (32) : 2457 - 2466
[17] Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy
Pernas, Sonia
Sanfeliu, Esther
Villacampa, Guillermo
Salvador, Javier
Perello, Antonia
Gonzalez, Xavier
Jimenez, Begona
Merino, Maria
Palacios, Patricia
Pascual, Tomas
Alba, Emilio
Villanueva, Lorea
Chillara, Samyukta
Ferrero-Cafiero, Juan Manuel
Galvan, Patricia
Prat, Aleix
Ciruelos, Eva
NPJ BREAST CANCER, 2024, 10 (01)
[18] Phase Ib study of ribociclib plus letrozole in Asian non-Japanese patients with hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESASIA
Yap, Yoon Sim
Ito, Yoshinori
Suarez-Vizcarra, Jose
Liu, Xiaochun
Han, Yu
Germa, Caroline
Chiu, Joanne
CANCER RESEARCH, 2018, 78 (04)
[19] Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data
Abdel-Razeq, Hikmat
Sharaf, Baha
AlMasri, Rama
Abdel-Razeq, Rashid
Tanninni, Faris
Khader, Omar
Salanna, Osama
Abunasser, Mahmoud
Edaily, Sarah
Abdulelah, Hazem
CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 1033 - 1041
[20] First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC)
Hortobagyi, G. N.
Stemmer, S. M.
Burris, H. A.
Yap, Y. S.
Sonke, G. S.
Paluch-Shimon, S.
Campone, M.
Blackwell, K.
Andre, F.
Winer, E. P.
Janni, W.
Verma, S.
Conte, P.
Arteaga, C. L.
Cameron, D.
Xuan, F.
Souami, F.
Miller, M.
Germa, C.
O'Shaughnessy, J.
ANNALS OF ONCOLOGY, 2016, 27

← 1 2 3 4 5 →